After sleeping on it, here are my thoughts on where we are FWIW (not much)
as I said earlier, I think the efficacy and safety profile of this trial have already priced mid pharma out.
Any mid pharma would perhaps offer a up front with royalties and milestones. Suppose they too offered $40M. the catch is they would want total control of the asset and to add it to their pipeline. We would become a minor interest partner in the deal. We would have same money with 0 control over 434.
the most beneficial outcome of a deal would be a total takeover with a B in the price. Clearly a deal is not possible at this stage.
Go it alone is likely to be in our best interest imo. The team has a clear vision on how future trials should be run if needed and we avoid becoming a shell with money that is waiting on another pharma to get 434 right or else we dissipate in to the abyss.
Anyway, I'll be quiet and wait to see how the next little bit unfolds.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)